Helius Medical Technologies, Inc.
TSX : HSM
OTCQB : HSDT

Helius Medical Technologies, Inc.

July 13, 2016 09:00 ET

Helius Medical Technologies Announces That Registration Statement on Form S-1 has Been Declared Effective

NEWTOWN, PENNSYLVANIA--(Marketwired - July 13, 2016) - Helius Medical Technologies, Inc. (TSX:HSM)(OTCQB:HSDT) ("Helius" or the "Company") announced today that the Securities and Exchange Commission ("SEC") has declared effective the Company's registration statement on Form S-1 relating to the resale of up to 11,953,115 shares of the Company's Class A common stock, without par value (the "Common Shares), 5,074,560 warrants to purchase shares of the Company's Class A common stock at an exercise price of CAD$1.50 per share (US$1.15 per share at the noon exchange rate as published by the Bank of Canada on July 12, 2016) (the "Warrants"), and 5,074,560 shares of our Class A common stock issuable upon the exercise of the Warrants held by certain securityholders of the Company named in the registration statement (the "Warrant Shares", and together with the Common Shares and the Warrants, the "Securities").

The registration statement, while effective, allows the selling securityholders named in the registration statement to publicly resell the Securities. Helius will not receive any proceeds from the sale of the Securities by the selling securityholders. Upon the cash exercise of the Warrants, Helius will receive the exercise price of the Warrants.

The registration statement may be accessed through the SEC's website at www.sec.gov. A copy of the prospectus relating to the offering may be obtained from Helius by writing Helius Medical Technologies, Inc. Suite 400, 41 University Drive Newtown, Pennsylvania 18940 or calling (215) 809-2018.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sales of these securities, in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a medical technology company focused on neurological wellness. Helius seeks to develop, license and acquire unique and non-invasive platform technologies that amplify the brain's ability to heal itself. Helius intends to file for FDA clearance for the PoNS™ device. For more information, please visit www.heliusmedical.com.

The Toronto Securities Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of the content of this news release.

Cautionary Disclaimer Statement:

Certain statements in this news release are not based on historical facts and constitute forward-looking statements or forward-looking information within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and Canadian securities laws ("forward-looking statements").

All statements other than statements of historical fact included in this news release are forward-looking statements that involve risks and uncertainties. Such forward-looking statements include, among others, statements regarding ongoing or planned clinical research, expected future development timelines, regulatory approvals, business initiatives and objectives and use of proceeds from financings or other business initiatives.

Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions.

There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure of the Company to achieve its business objectives and other risks detailed from time to time in the filings made by the Company with securities regulators.

The reader is cautioned that assumptions used in the preparation of any forward-looking statements may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking statement. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. Risks and uncertainties about the Company's business are more fully discussed in the Company's disclosure materials, including the short form prospectus filed in connection with the Offering, its Annual Report on Form 10-K filed with the United States Securities and Exchange Commission and the Canadian securities regulators and which can be obtained from either at www.sec.gov or www.sedar.com.

The forward-looking statements contained in this news release are made as of the date of this news release and the Company assumes no obligation to update any forward-looking statement or to update the reasons why actual results could differ from such statements except to the extent required by law.

Contact Information